StreetInsider.com News Articles

Form ARS Xtant Medical Holdings, For: Dec 31

Tue, 23 Jun 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260623/26675741.html

Form ARS Xtant Medical Holdings, For: Dec 31

Tue, 23 Jun 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260623/26675741.html

Form DEFA14A Xtant Medical Holdings,

Tue, 23 Jun 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260623/26675727.html

Form DEFA14A Xtant Medical Holdings,

Tue, 23 Jun 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260623/26675727.html

Form DEF 14A Xtant Medical Holdings, For: Jun 23

Tue, 23 Jun 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260623/26675692.html

Form DEF 14A Xtant Medical Holdings, For: Jun 23

Tue, 23 Jun 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260623/26675692.html

Form SD Xtant Medical Holdings,

Fri, 29 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260529/26575027.html

Form SD Xtant Medical Holdings,

Fri, 29 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260529/26575027.html

BTIG Reiterates Buy Rating on Xtant Medical (XTNT)

Wed, 13 May 2026 10:38:03 -0400

BTIG analyst Ryan Zimmerman reiterated a Buy rating and $1.00 price target on Xtant Medical (NYSE: XTNT).

The analyst commented: "We maintain our Buy and $1 PT following 1Q26 results. XTNT reported rev. of $20.9M (-28.7% Y/Y) and EPS of $(0.02), slightly ahead of BTIG/Consensus estimates of $18.8M/$20.2M as Spinal Hardware saw higher sales ($5.3M) vs. estimates. XTNT saw declines in both Orthobiologics (-13.6% Y/Y) and Spinal Implants (-52.9% Y/Y) as it laps the sale of its of Coflex and CoFix assets as well as the benefits from license revenue. GMs of ~57.3% (-420bps Y/Y) were below expectations as XTNT generated

Form S-8 POS Xtant Medical Holdings,

Wed, 13 May 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260513/26481799.html

Form S-8 POS Xtant Medical Holdings,

Wed, 13 May 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260513/26481799.html

Form S-8 POS Xtant Medical Holdings,

Wed, 13 May 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20260513/26481782.html

Form S-8 POS Xtant Medical Holdings,

Wed, 13 May 2026 07:32:00 -0400

si-local-file:///var/storage/secattach/20260513/26481782.html

Form S-8 POS Xtant Medical Holdings,

Wed, 13 May 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260513/26481764.html

Form S-8 POS Xtant Medical Holdings,

Wed, 13 May 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260513/26481764.html

Form S-8 POS Xtant Medical Holdings,

Wed, 13 May 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260513/26481755.html

Form S-8 POS Xtant Medical Holdings,

Wed, 13 May 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260513/26481755.html

Form 10-Q Xtant Medical Holdings, For: Mar 31

Wed, 13 May 2026 07:16:00 -0400

si-local-file:///var/storage/secattach/20260513/26481631.html

Form 10-Q Xtant Medical Holdings, For: Mar 31

Wed, 13 May 2026 07:16:00 -0400

si-local-file:///var/storage/secattach/20260513/26481631.html

Form 8-K Xtant Medical Holdings, For: May 13

Wed, 13 May 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260513/26481537.html

Form 8-K Xtant Medical Holdings, For: May 13

Wed, 13 May 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260513/26481537.html

Xtant Medical Holdings (XTNT) Misses Q1 EPS by 1c ; Offers Guidance

Wed, 13 May 2026 07:04:53 -0400

Xtant Medical Holdings (NYSE: XTNT) reported Q1 EPS of ($0.02), $0.01 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $22 million.

GUIDANCE:

Xtant Medical Holdings sees FY2026 revenue of $101-105 million, versus the consensus of $97.34 million.

For earnings history and earnings-related data on Xtant Medical Holdings (XTNT) click here.

Xtant Medical Holdings (XTNT) Misses Q1 EPS by 1c ; Offers Guidance

Wed, 13 May 2026 07:04:53 -0400

GUIDANCE:

Xtant Medical Holdings sees FY2026 revenue of $101-105 million, versus the consensus of $97.34 million.

For earnings history and earnings-related data on Xtant Medical Holdings (XTNT) click here.

Xtant Medical Reports First Quarter 2026 Financial Results

Wed, 13 May 2026 07:00:00 -0400

Raises full-year 2026 revenue guidance to a range of $101-$105 million

Significantly strengthens balance sheet

Enters into exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST^®Bellows product for high-performance hemostasis; hires Dilon's U.S. sales team

BELGRADE, Mont., May 13, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the first quarter ended March 31, 2026.

Xtant Medical Reports First Quarter 2026 Financial Results

Wed, 13 May 2026 07:00:00 -0400

Raises full-year 2026 revenue guidance to a range of $101-$105 million

Significantly strengthens balance sheet

Enters into exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST^®Bellows product for high-performance hemostasis; hires Dilon's U.S. sales team